VivoSeq
Cardiovascular

Myocarditis

15

Pipeline Programs↗

8

Active Trials↗

8

Companies Involved↗

Myocarditis is an emerging landscape with 15 programs across 8 companies. The most active players are Bristol-Myers Squibb, Prism Pharmaceuticals, Novartis. 2 therapies are approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

45/100

Pipeline Velocity

11/100

Mech. Concentration

56/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 2P

Prism Pharmaceuticals

1 program

Phase 2Novartis logo

Novartis

1 program

Phase 2Pfizer logo

Pfizer

2 programs

Phase 3M

Milestone Pharmaceuticals Inc.

1 program

ApprovedP

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

83%

Small molecule

15 of 18 classified programs — the dominant modality here.

17%ALL OTHERSRadiopharmaceutical211%Protein / enzyme16%

Small molecule leads; the ring shows all 18 classified programs, each share of the total. Modality classified for 100% of 20 pipeline programs.

Analysis

Trial Status

14

clinical trials

Completed6 · 43%
Not yet recruiting4 · 29%
Recruiting3 · 21%
Active, not recruiting1 · 7%

Clinical Trials

Trial Activity

14 trials

Abatacept in Immune Checkpoint Inhibitor Myocarditis
Recruiting·MMassachusetts General Hospital·Phase 3·NCT05335928·390 enrolled
MYTHS-MR Trial (MYocarditis THerapy With Steroids in Patients With Mildly Reduced Ejection Fraction)
Recruiting·UUniversity Hospital, Antwerp·Phase 3·NCT05974462·174 enrolled
MYTHS - MYocarditis THerapy With Steroids
Recruiting·NNiguarda Hospital·Phase 3·NCT05150704·288 enrolled
AbataCept for the Treatment of Immune-cHeckpoint Inhibitors Induced mYocarditiS
Active, not recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT05195645·21 enrolled
The Efficacy and Safety of Tofacitinib in Patients With Glucocorticoid Resistant ICIs-related Myocarditis
Not yet recruiting·SShanghai Zhongshan Hospital·Phase 2·NCT06393972·25 enrolled
Pulse Corticosteroids Or/and Immunoglobulins to Treat Fulminant Myocarditis
Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT06896253·120 enrolled
Assessment of Myocarditis After Replication-Deficient Smallpox Immunization
Not yet recruiting·—·N/A·NCT05513313·2,350 enrolled
Outcome of Clinical Phenotypes of Pediatric Myocarditis at Assiut University Children Hospital
Not yet recruiting·—·N/A·NCT07175948·100 enrolled
Phase II Randomized Study of Muromonab-CD3, Cyclosporine, Methylprednisolone, and Prednisone in Patients With Giant Cell Myocarditis
Completed·MMayo Clinic·Phase 2·NCT00004482·40 enrolled
Monitoring Drug-induced Myocarditis (CardiTOX)
Completed·GGroupe Hospitalier Pitie-Salpetriere·N/A·NCT03855982·6,000 enrolled
Myocarditis Treatment Trial
Completed·UUniversity of Utah·Phase 2·NCT00000524
Micophenolate Mofetil Versus Azathioprine in Myocarditis
Completed·II.M. Sechenov First Moscow State Medical University·Phase 3·NCT05237323·50 enrolled
Study of Muromonab-CD3 and Cyclosporine in Patients With Giant Cell Myocarditis
Completed·MMayo Clinic·N/A·NCT00027443·40 enrolled
Monocentric Interventionnal Pilot Study Pilot Study Evaluating Somatostatin Receptor's PET Imaging to Detect Inflammatory Phases of Myocarditis
Completed·CCentral Hospital, Nancy, France·Preclinical·NCT03347760·33 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)